Hyaluronic acid, Methylsulfonylmethane, High-performance liquid chromatography

Osteoarthritis can be treated by taking oral supplements containing compounds that can nourish bones and joints such as hyaluronic acid, methylsulfonylmethane (MSM), chondroitin, glucosamine, and collagen. This study aimed to develop and validate tests for analyzing two compounds, namely, hyaluronic acid and MSM, simultaneously and to determine both their levels in a mixed sample.

Methods: Hyaluronic acid derivatization was carried out using fluoromethylisoxycarbonyl chloride and then analyzed by liquid chromatography with fluorescence detection, while MSM was analyzed using gas chromatography. After the development of optimal conditions for each separation, system suitability tests were developed and calibration curves used for tests of accuracy and precision as well as for level determination. Hyaluronic acid was detected at an excitation wavelength of 255 nm and emission wavelength of 330 nm. The mobile phase used was acetonitrile-acetate pH 4.2 (1:4) with a flow rate of 1.0 mL/min.

Results: The developed method was linear (r=0.9983) in the range of 5–50 ppm and the limits of detection (LOD) and quantitation (LOQ) were 3.55 and 11.84 ppm, respectively. The initial column temperature for MSM analysis was 110°C and the mobile phase used was nitrogen gas at a flow rate of 0.8 mL/min. The method was linear (r=0.9998) in the range of 4000–15,000 ppm and the LOD and LOQ were 332.90 and 1109.67 ppm, respectively.

Conclusion: A simulated sample containing both compounds was assayed to contain 98.63% hyaluronic acid and 99.35% MSM.

Keywords: Hyaluronic acid, Methylsulfonylmethane, High-performance liquid chromatography, Gas chromatography, Fluorenlymethylisoxycarbonyl chloride, Component, Optimization, Validation.

INTRODUCTION

Food supplements are products that contain nutrients and excipients and are available as capsules, tablets, powders, or liquids; they are used in cases where dietary insufficiency of their ingredients can lead to ill health [1]. Food supplements are only complementary, and not intended to be used as substitutes for a normal diet. These supplements usually contain chemical compounds that function as nutrients in the body and can aid in supplying the specific nutritional needs of those with certain health conditions. For example, protein supplementation is used to prevent joint pain and help tighten the skin [2].

Two compounds that are often used in supplements to prevent these conditions are hyaluronic acid and methylsulfonylmethane (MSM), both of which can nourish bones and joints [1]. There are a number such supplement products sold to treat the symptoms of osteoarthritis and these usually contain glucosamine sulfate, chondroitin sulfate, MSM, Celadrin, nattokinase, hyaluronic acid, black catechu, skullcap, Boswellia serrata, and curcumin [3]. This study developed analytical methods for only hyaluronic acid and MSM because separation all these components require high-performance gradient liquid chromatography, while only isocratic high-performance liquid chromatography (HPLC) was available.

Hyaluronic acid exists in various molecular sizes in biological tissues and fluids and can be degraded by both normal physiological or pathological conditions [4]. It consists of linear macromolecular chains of repeated glucuronic acid and N-acetyl-D-glucosamine subunits that form glucosamine when hydrolyzed [5]. Hyaluronic acid molecules of different weights have different rheological and biological properties, and this, coupled to its intrinsic biocompatibility and viscoelastic physical character, means that it has been used as a treatment for osteoarthritis [6]. Thus, hyaluronic acid is commonly used as a supplement to maintain joint health and to control tissue hydration [7].

Methylsulfonylmethane is an organosulfur compound that is commonly used as a food supplement for the prevention of metabolic diseases since the amount of MSM and sulfur in the body decreases with age [8].

Hyaluronic acid does not contain any chromophores but can be derivatized with fluorescent compounds. Reagents that are often used for such derivatization before analysis include orthophthalaldehyde, phenyl isothiocyanate (PITC), and 9-fluorenylmethoxycarbonyl chloride [3].

Hyaluronic acid has previously been analyzed are using high-performance size-exclusion liquid chromatography [9], while a study using HPLC conducted by Harmita (2015) used a silica phase with phosphoric and potassium hydroxide in conjunction with UV detectors. Methylsulfonylmethane can be analyzed by gas chromatography (GC), with the 39th edition of the United States Pharmacopeia Edition 39 providing a method using dimethylpolysiloxane gum columns with a mobile phase of helium gas and flame ionization detection.

Here, we conducted an analysis of a mixture of hyaluronic acid and methylsulfonylmethane using HPLC in dimethyl sulfoxide with fluorescence detection for hyaluronic acid, and GC with flame ionization detection for methylsulfonylmethane analysis. Hyaluronic acid was derivatized with 9-fluorenylmethylketocarbonyl chloride, which was chosen because it can react with primary and secondary amine groups.

MATERIALS AND METHODS

Materials

Chemicals were purchased from the following suppliers: Hyaluronic acid standard (Sigma-Aldrich); methylsulfonylmethane standard (Merck); magnesium stearate (Merck); Amylum Oryzae (Merck); 9-fluorenylmethylketocarbonyl chloride (Merck); glacial acetic acid (Merck); chloride acid (Merck); methanol pro HPLC (Merck); aqua pro

The 4th International Conference on Global Health 2019
injection (Ikapharmindo Putramas); aquadest (Brataco); acetonitrile pro HPLC (Merck); NaOH (Merck); boric acid (Merck); anhydrous sodium acetate (Merck); nitrogen (Merck); and hydrogen (Merck).

**Equipment**

The HPLC (Shimadzu®) consisted of pumps, Shimadzu® C18 columns, RF 20A Fluorescence detectors, manual injectors, a computer data processor, and HPLC syringes (SGE®, Australia). A Shimadzu® GC model GC-17A equipped with flame ionization detector, a capillary column with a length of 30 m, inner diameter of 0.53 mm, and film thickness of 5 µm with stationary phase G2 was used with a 10 µl micro-syringe (Hamilton Co.Nevada®).

**Procedures**

**Standard hyaluronic acid solution**

Two hundred milligrams of hyaluronic acid standard was dissolved in 100 mL of 0.1 N HCl and diluted to a concentration of 10 µg/mL.

**Standard methylsulfonylmethane solution**

Four milligrams of methylsulfonylmethane was dissolved in 1 mL of methanol, sonicated at 50°C for 1 min, and cooled to room temperature.

**Wavelength optimization**

The hyaluronic acid standard (300 µL) was pipetted into a test tube and 300 µl of borate buffer and 300 µl of 1.5 mM fluoroethylmethoxy carbonyl chloride (FMOC-Cl) reagent added. The mixture was vortexed for 20 s and allowed to stand for 2 min before injection of 20 µL into the HPLC to determine the excitation and emission wavelengths. This was achieved by varying excitation wavelengths at 255 nm and using three emission wavelengths (320, 325, and 330 nm). The selected wavelengths were those that produced the largest peak area.

**Determination of optimal analytic conditions**

A standard solution of hyaluronic acid with a concentration of 50 µL/mL as much as 100 µL each into the test tube and 100 µL of borate buffer pH 9.3, the solution is then added FMOC-Cl reagent to the selected volume. The mixture was vortexed for 20 s and allowed to react before HPLC analysis. Twenty microlitter aliquots were analyzed using various combinations of the mobile phase of acetate (pH 4.2)-acetonitrile at 1:2, 2:1, 3:1, and 1:4 and with different flow rates of 0.8, 1.0, or 1.2 mL/min.

One microliter of a standard solution of methylsulfonylmethane at a concentration of 4000 ppm was injected into the GC and determined of optimal analysis conditions was performed by programing various initial column temperatures of the 100°C, 110°C, or 120°C and various flow rates of 0.8, 1.0, or 1.2 mL/min. The initial temperature was increased by 1°C/min to 250°C and the injector and detector temperatures were set to 250°C. The retention time, area, follow-up factor, number of theoretical plates, column efficiency (HETP), and resolution were determined for each condition, and the one that had the shortest retention time, the largest number of theoretical plates (N), the smallest HETP, the smallest follow-up factor (TF), and the best separation with a resolution of 1.5 or more was selected.

**Validation of analytical methods**

One microliter of 1000 mL/mL of hyaluronic acid was placed into a 10 mL flask and used to produce a 100-ppm solution, which was then used to produce solution of 10, 20, 30, and 50 µg/mL. Samples were then derivatized and 20.0 µL of each was analyzed. A plot of peak area (y) versus concentration (x) produced a straight line with a correlation coefficient (r) of 0.999 (Fig. 1).

Different volumes (200 µL, 400 µL, 800 µL, 1000 µL, 1200 µL, and 1500 µL) of the 50,000 ppm methylsulfonylmethane standard solution were each added to 5 mL volumetric flasks, which were then mixed using mobile phase solvent and then mixed to produce concentrations of 2000, 4000, 8000, 10,000, 12,000, and 15,000 ppm. One microliter of each solution was then injected into the GC and analyzed using the optimized conditions. The data were then used to produce a curve of peak area versus concentration. Result shown in Fig. 2.

Accuracy and precision tests for hyaluronic acid were carried out by analyzing simulated samples, which were produced by adding pure analytes added to the pharmaceutical vehicle. The concentrations used were low, medium, and high, namely, concentrations of 80%, 100%, and 120% of the target concentration. The 100% sample was made by dissolving 4 mg of the matrix of capsule fillers in a mixture of 20 mg of hyaluronic acid and 32 mg of methylsulfonylmethane. The 80% concentration was prepared by dissolving 3.2 mg of matrix in a mixture of 16 mg hyaluronic acid and 25.6 mg methylsulfonylmethane. The 120% concentration was produced by dissolving 4.8 mg of matrix in a mixture of 24 mg hyaluronic acid and 38.4 mg methylsulfonylmethane.

All samples were dissolved in 100 mL 0.1 N HCl then pipette 1 mL and put into a 10 mL flask. Samples were filtered through a 0.45 µm membrane and 300 µL of each solution was added to 300 µL borate buffer pH 9.3 and 300 µL FMOC-Cl 1.5 mM (in acetonitrile) then the sample was filtered using a filter. Twenty microsufers of each sample were injected into the HPLC in triplicate and the percent recovery (% recovery) and % KV were calculated using calibration curves to determine concentrations. Accuracy was considered acceptable if the percentage of recovery (% UPK) lays between 98% and 102% of target. Precision was considered acceptable if % KV was 2% or less.

Accuracy and precision tests for methylsulfonylmethane were conducted as for hyaluronic acid. The 100% concentration was produced by dissolving 5 mg of capsule matrix with 5 mg hyaluronic acid and 20 mg methylsulfonylmethane. The 80% concentration was

![Fig 1: Calibration Curve for hyaluronic acid](Image)

![Fig 2: Calibration curve for methylsulfonylmethane](Image)
produced by dissolving 5 mg of matrix with a mixture of 4 mg hyaluronic acid and 16 mg methylsulfonylmethane. The 120% concentration was produced by dissolving 5 mg of matrix with 6 mg hyaluronic acid and 24 mg methylsulfonylmethane, methanol was used as a solvent and samples were shaken until dissolved. Each sample was passed through a 0.45 μm filter and 1 mL placed into a 10 mL volumetric flask, which was filled to volume with n-hexane. One microliter of each sample was analyzed in triplicate, and the recover (% recovery) and % KV calculated using calibration curves to determine concentrations. Accuracy was considered acceptable if the percentage of recovery (% UPK) lay between 98% and 102% of target. Precision was considered acceptable if % KV was 2% or less.

Selectivity

The standard hyaluronic acid solution was derivatized and then 20 μL was injected into HPLC and the chromatograms examined for any differences in retention time between the sample and the standard and to determine whether or not another peak appeared at the hyaluronic acid retention time in the sample solution.

The 40,000 ppm methylsulfonylmethane standard solution of was vortexed to homogeneity and 1 μL injected into the GC. The same 20 μL was injected into HPLC and the chromatograms examined to determine whether any matrix compounds eluted at the same time as methylsulfonylmethane.

RESULTS AND DISCUSSION

The results of method optimization for hyaluronic acid are summarized in Tables 1-3. Based on the data, a wavelength of 330 nm with a mobile phase with a ratio 1:4 and a flow rate of 1.0 mL/min were selected as the optimal conditions because these produced relatively fast retention times, a number of theoretical plates with a relatively small HETP, and a tailing factor close to one.

Results for methylsulfonylmethane analysis optimization are shown in Tables 4-6. This showed that higher initial column temperatures and faster flow rates produced smaller retention times. The initial temperature of the column used was chosen to be 110°C with a flow rate of 0.8 mL/min because this produced relatively faster retention times, quite a number of theoretical plates, a relatively small HETP, and a tailing factor of close to one. The 120°C temperature was not chosen because it resulted in the peak of the chromatogram at the retention time with the peak of the solvent chromatogram used so that it was feared that the proximity of the two chromatographic peaks could disrupt the chromatogram peak of methylsulfonylmethane compound. The 1.0 mL/min and 1.2 mL/min flow rates were not chosen because they resulted in an unfavorable separation between the substance and solvent peaks.

The conformity tests were carried out to qualify the optimized method by running six consecutive tests under the same conditions. This needs

Table 1: Effect of emission wavelength variations on retention time, peak area, theoretical plate, tailing factor, and HETP of hyaluronic acid derivatives

| Excitation wavelength (nm) | Emission wavelength (nm) | Retention time (min) | Peak area (μV/s) | Theoretical plates (N) | Tailing factor (Tf) | HETP (cm) |
|---------------------------|--------------------------|----------------------|------------------|------------------------|-------------------|-----------|
| 255                       | 320                      | 5.990                | 2909568          | 892                    | 1.219             | 168.14    |
|                           | 325                      | 5.981                | 4819277          | 869                    | 1.207             | 172.60    |
|                           | 330                      | 5.999                | 6855959          | 809                    | 1.193             | 168.73    |

Table 2: Effect of variations in the composition on the mobile phase with respect to retention time, peak area, theoretical plate, tailing factor, and HETP of hyaluronic acid derivatives

| Mobile phase | Mobile phase ratio | Retention time (min) | Peak area (μV/s) | Theoretical plates (N) | Tailing factor (Tf) | HETP (cm) |
|--------------|--------------------|----------------------|------------------|------------------------|-------------------|-----------|
| Acetonitrile-acetic | 1:2 | 41.132 | 2346676 | 2049 | 0.769 | 7368.27 |
| buffer pH 4.2       | 1:4 | 5.999 | 5688541 | 1019 | 1.241 | 147.22  |
|                      | 2:3 | 20.637 | 8123089 | 1626 | 1.563 | 851.63  |

Table 3: Relationship of flow rate to retention time, peak area, theoretical plate, tailing factor, and HETP of hyaluronic acid derivatives

| Flow rate (mL/min) | Retention time (min) | Peak area (μV/s) | Theoretical plates (N) | Tailing factor (Tf) | HETP (cm) |
|--------------------|----------------------|------------------|------------------------|-------------------|-----------|
| 0.8                | 7.476                 | 2955712          | 1305                   | 1.221             | 114.99    |
| 1.0                | 5.999                 | 3245385          | 1289                   | 1.210             | 112.99    |
| 1.2                | 5.026                 | 3157540          | 694                    | 1.217             | 216.29    |

Table 4: The relationship between retention time, peak area, number of theoretical plates, column efficiency, resolution, and tailing factor for methylsulfonylmethane at various flow rates and an initial column temperature of column 100°C

| Column temperature | Flow rate (mL/min) | Retention time (min) | Peak area (μV/s) | Theoretical plates (N) | Tailing factor (Tf) | HETP (cm) |
|--------------------|--------------------|----------------------|------------------|------------------------|-------------------|-----------|
| 100°C              | 0.8                | 3.837                | 47392             | 1481085                | 0.996             | 2.03      |
|                    | 1.0                | 3.845                | 34775             | 2563896                | 0.979             | 1.17      |
|                    | 1.2                | 3.826                | 33991             | 1388627                | 0.982             | 2.16      |

HETP: Height equivalent to a theoretical plate
Table 5: The relationship between retention time, peak area, number of theoretical plates, column efficiency, resolution, and tailing factor for methylsulfonylmethane at various flow rates and an initial column temperature of column 110°C

| Column temperature | Flow rate (mL/min) | Retention time (min) | Peak area (μV/s) | Theoretical plates (N) | Tailing factor (Tf) | HETP (cm) |
|--------------------|--------------------|----------------------|------------------|------------------------|--------------------|-----------|
| 110°C              | 0.8                | 3.412                | 50311            | 30283.17               | 0.994              | 0.99      |
|                    | 3.386              | 50875                | 26149.43        | 1.002                  | 1.15               |
|                    | 3.396              | 50656                | 24017.07        | 0.856                  | 1.25               |
|                    | 1.0                | 2.734                | 50240           | 17840.12               | 0.822              | 1.68      |
|                    | 2.722              | 50037                | 207320.2        | 0.932                  | 0.14               |
|                    | 2.722              | 50008                | 20763.31        | 0.976                  | 1.44               |
|                    | 1.2                | 2.296                | 51349           | 8779.278               | 0.828              | 3.42      |
|                    | 2.308              | 49178                | 110114.2        | 0.654                  | 2.72               |
|                    | 2.306              | 51359                | 13757.95        | 0.903                  | 2.18               |

HETP: Height equivalent to a theoretical plate

Table 6: The relationship between retention time, peak area, number of theoretical plates, column efficiency, resolution, and tailing factor for methylsulfonylmethane at various flow rates and an initial column temperature of column 120°C

| Column temperature | Flow rate (mL/min) | Retention time (min) | Peak area (μV/s) | Theoretical plates (N) | Tailing factor (Tf) | HETP (cm) |
|--------------------|--------------------|----------------------|------------------|------------------------|--------------------|-----------|
| 120°C              | 0.8                | 3.077                | 55413            | 20548.17               | 0.957              | 3.41      |
|                    | 3.048              | 56748                | 18564.26        | 1.025                  | 1.50               |
|                    | 3.092              | 52336                | 26465.26        | 1.335                  | 3.00               |
|                    | 1.0                | 2.524                | 58412           | 23154.15               | 1.025              | 1.50      |
|                    | 2.486              | 55648                | 26465.26        | 1.335                  | 3.00               |
|                    | 2.598              | 54852                | 24515.21        | 1.051                  | 1.80               |
|                    | 1.2                | 2.054                | 53215           | 26648.04               | 1.326              | 1.90      |
|                    | 1.984              | 52156                | 19354.51        | 1.512                  | 2.98               |
|                    | 2.012              | 50123                | 23645.35        | 1.320                  | 2.87               |

HETP: Height equivalent to a theoretical plate

Table 7: Conformity test results for the hyaluronic acid system

| Concentration (μL/mL) | Retention time (min) | Peak area (μV/s) | Theoretical plates (N) | Tailing factor (Tf) | HETP (cm) | Average | Standard deviation | %KV |
|-----------------------|----------------------|------------------|------------------------|--------------------|-----------|---------|---------------------|-----|
| 20                    | 6.463                | 1643597          | 2583                   | 0.993              | 58.08     | 1669780 | 18605.52            | 1.11|
| 6.459                 | 1683699              | 2477             | 0.976                  | 60.55              |
| 6.432                 | 1685624              | 2418             | 0.872                  | 62.03              |
| 6.409                 | 1651491              | 2317             | 0.838                  | 64.73              |
| 6.391                 | 1668269              | 2164             | 0.902                  | 69.32              |
| 6.423                 | 1685811              | 2302             | 0.895                  | 65.77              |

HETP: Height equivalent to a theoretical plate

Table 8: Conformity test results for the methylsulfonylmethane system

| Concentration (μL/mL) | Retention time (min) | Peak area (μV/s) | Theoretical plates (N) | Tailing factor (Tf) | HETP (cm) | Average | Standard deviation | %KV |
|-----------------------|----------------------|------------------|------------------------|--------------------|-----------|---------|---------------------|-----|
| 4000                  | 3.327                | 54266            | 22161.562              | 0.993              | 0.14      | 54285.17 | 57.1084             | 0.11|
| 3.336                 | 54321                | 21209.208        | 1.294                  | 0.14               |
| 3.347                 | 54271                | 18836.078        | 0.976                  | 0.22               |
| 3.338                 | 54325                | 15800.732        | 1.32                   | 0.2                |
| 3.338                 | 54380                | 2295.4957        | 1.296                  | 0.13               |
| 3.347                 | 54238                | 17840.273        | 1.193                  | 0.17               |

HETP: Height equivalent to a theoretical plate

Accuracy is a value that describes the closeness of test results to the actual level of the analyte in the sample. Accuracy can be defined as the % recovery, i.e., the percentage of the test result relative to actual content.

Linear calibration curves are used to calculate the concentrations of compounds in a sample. A calibration curve for methylsulfonylmethane was produced that contained six points between 2000 and 15,000 μg/mL. The linear equation was y=15.596x−8673.5, where x is the concentration and y is the chromatogram peak area, and the correlation coefficient was 0.9998 (Table 9).

For hyaluronic acid compounds, a 6-point curve between 5 and 50 μg/mL produced a line with the equation y = 75714x−1859406 and a correlation coefficient of 0.9983 Table 10.

Accuracy is a value that describes the closeness of test results to the actual level of the analyte in the sample. Accuracy can be defined as the % recovery, i.e., the percentage of the test result relative to actual content.
of the sample and should fall within 98–120% to be acceptable [9]. In this study, this was conducted by producing simulated samples by from mixtures of the two analytes with appropriate pharmaceutical excipients. The mixtures were first prepared, derivatized (for hyaluronic acid) and then analyzed using high-performance fluorescence detector liquid chromatography. Methylsulfonylmethane was prepared then analyzed using by GC. The simulated samples were produced at three different concentrations, namely, 80%, 100%, and 120%, which corresponded to hyaluronic acid concentrations of 16 μg/mL, 20 μg/mL, and 24 μg/mL, while the simulated methylsulfonylmethane samples contained of 3200 μg/mL, 4000 μg/mL, and 4800 μg/mL, respectively. Recovery of methylsulfonylmethane ranged between 100.37% and 101.50%, while those for hyaluronic acid ranged between 98.59% and 100.42%, both of which were considered excellent. Result shown in Tables 11 and 12.

### Table 9: Calibration curve data, LOD, and LOQ for methylsulfonylmethane

| Concentration (μL/mL) | Peak area (μV/s) | y=a+bx | (y−yi)² | S_y/σ | LOD (μg/mL) | LOQ (μg/mL) |
|-----------------------|-----------------|--------|---------|-------|-------------|-------------|
| 2000                  | 20793           | 22518.5| 2977350.25 | 1730.6455 | 332.9 | 1109.67 |
| 4000                  | 54105           | 53710.5| 155630.25  |       |             |             |
| 8000                  | 118345          | 116094.5| 5064750.25 |       |             |             |
| 10,000                | 148495          | 147286.5| 1460472.25 |       |             |             |
| 12,000                | 177244          | 178478.5| 1523990.25 |       |             |             |
| 15,000                | 224373          | 225266.5| 798342.25  |       |             |             |
| N=6                   |                 |        | 119980535.5|       |             |             |

LOD: Limit of detection, LOQ: Limit of quantification

### Table 10: Calibration curve data, LOD, and LOQ for hyaluronic acid

| Concentration (μL/mL) | Peak area (μV/s) | y=a+bx | (y−yi)² | S_y/σ | LOD (μg/mL) | LOQ (μg/mL) |
|-----------------------|-----------------|--------|---------|-------|-------------|-------------|
| 5                     | 339912          | 237976 | 0390948096 | 85086.4131 | 3.55  | 11.84 |
| 10                    | 603443          | 616546 | 130826  | 624493025 |       |             |
| 20                    | 245385          | 373686 | 220980804 |       |             |             |
| 30                    | 74688           | 130826 | 151475044 |       |             |             |
| 40                    | 925521          | 887966 | 410378025 |       |             |             |
| 50                    | 685411          | 645106 | 624493025 |       |             |             |
| N=6                   |                 |        | 11980535.5 |       |             |             |

LOD: Limit of detection, LOQ: Limit of quantification

### Table 11: Accuracy and precision data for hyaluronic acid

| Concentration (μg/mL) | Peak area (μV/s) | Measured concentration (μg/mL) | % Recovery | Average | Standard deviation | KV (%) |
|-----------------------|-----------------|-------------------------------|------------|---------|--------------------|--------|
| 8                     | 245652          | 7.886864                      | 98.59      | 99.03   | 0.7858             | 0.79   |
| 10                    | 2464738         | 7.994981                      | 99.94      |         |                    |        |
| 30                    | 245437          | 7.885345                      | 98.57      |         |                    |        |
| 40                    | 2619691         | 10.04154                      | 100.42     | 100.34  | 0.105              | 0.1    |
| 50                    | 2618220         | 10.02211                      | 100.22     |         |                    |        |
| N=6                   |                 |                               |            | 100.96  | 0.6614             | 0.66   |

### Table 12: Accuracy and precision data for methylsulfonylmethane

| Concentration (μg/mL) | Peak area (μV/s) | Measured concentration (μg/mL) | % Recovery | Average | Standard deviation | KV (%) |
|-----------------------|-----------------|-------------------------------|------------|---------|--------------------|--------|
| 3200                  | 41736           | 32.322.07                     | 101.01     | 100.96  | 0.5696             | 0.56   |
| 4000                  | 41416           | 321.1689                      | 100.37     |         |                    |        |
| 41983                 | 41963           | 324.8044                      | 101.5      |         |                    |        |
| 54208                 | 45136           | 4031.899                      | 100.8      | 100.65  | 0.1302             | 0.13   |
| 54107                 | 54020           | 4025.423                      | 100.64     |         |                    |        |
| 54031                 | 54010           | 4020.55                       | 100.51     |         |                    |        |
| 54019                 | 54019           | 4019.204                      | 100.48     |         |                    |        |
| 4800                  | 66776           | 4837.747                      | 100.79     | 100.86  | 0.0689             | 0.07   |
| 66879                 | 66879           | 4844.351                      | 100.92     |         |                    |        |
| 66832                 | 66832           | 4841.338                      | 100.86     |         |                    |        |

### Table 13: Quantification data for hyaluronic acid levels in supplements

| Concentration (μg/mL) | Peak area (μV/s) | Measured concentration (μg/mL) | % Recovery | Average | Standard deviation | KV (%) |
|-----------------------|-----------------|-------------------------------|------------|---------|--------------------|--------|
| 10                    | 2609213         | 9.9031                        | 99.03      | 98.63   | 0.3488             | 0.35   |
| 2604953               |                | 9.8469                        | 98.47      |         |                    |        |
| 2604378               |                | 9.8393                        | 98.39      |         |                    |        |
Precision reflects the reproducibility of results from multiple analyzes of the same material and is measured by % KV. In general, % KV values below 2% are considered acceptable [9]. Here, the % KV was 0.07%–0.56% for methylsulfonylmethane and 0.10%–0.79% for hyaluronic acid, both of which were considered acceptable.

To determine the levels of the two compounds, the samples were prepared containing both. Hyaluronic acid was derivatized using FMOC-Cl first and then analyzed HPLC to yield a sample content of 98.63%. Meanwhile, GC indicated a methylsulfonylmethane content of 99.35%. Result shown in Tables 13 and 14.

CONCLUSION

The optimum condition for analysis of hyaluronic acid by HPLC was with an excitation wavelength 255 nm and emission wavelength of 330 nm and with a mobile phase of acetonitrile-acetate pH 4.2 (1:4) at a flow rate of 1.0 mL/min. The optimum conditions for the analysis of methylsulfonylmethane by GC were with an initial temperature of column 110°C and a subsequent increase of 1°C/min to a temperature of 200°C, with an injector temperature of 250°C, a detector temperature of 250°C, and a nitrogen carrier gas flow rate of 0.80 mL/min.

The validation conducted here consisted of selectivity, linearity, detection and quantitation limit, and accuracy and precision tests. Both methods fulfilled the applicable criteria with respect to these analyses. For hyaluronic acid, the correlation coefficient was 0.9983 in a concentration range of 5–50 μg/mL and the LOD and LOQ values were 3.55 μg/mL and 11.84 μg/mL, respectively. Accuracy values as assessed by recover were 98.59–100.42% and precision as expressed by % KV was below 2%. For methylsulfonylmethane, the correlation coefficient was 0.9998 in the range of 2000–15,000 μg/mL and the LOD and LOQ were 332.90 μg/mL and 1109.67 μg/mL, respectively. Accuracy ranged between 100.37% and 101.50% and precision was below 2%.

A simulated sample containing both compounds was assessed to contained 98.63% hyaluronic acid and 99.35% methylsulfonylmethane.

For further research, hydrolysis of hyaluronic acid compounds is needed to obtain a more sensitive method.

REFERENCES

1. Cañibano-Hernández A, Saenz Del Burgo L, Espona-Noguera A, Orive G, Hernández RM, Criiza J, et al. Hyaluronic acid enhances cell survival of encapsulated insulin-producing cells in alginate-based microcapsules. Int J Pharm 2019;557:192-8.
2. Tokita Y, Okamoto A. Hydrolytic degradation of hyaluronic acid. Polym Degrad Stab 1995;48:269-73.
3. Faust HJ, Sommerfeld SD, Rathod S, Rittenbach A, Ray Banejeje S, Tsai BM, et al. A hyaluronic acid binding peptide-polymer system for treating osteoarthritis. Biomaterials 2018;183:93-101.
4. Gocmen G, Gonul O, Oktay NS, Yarat A, Goker K. The antioxidant and anti-inflammatory efficiency of hyaluronic acid after third molar extraction. J Craniomaxillofac Surg 2015;43:1033-7.
5. Lin A, Nguy CH, Shic F, Ross BD. Accumulation of methylsulfonylmethane in the human brain: Identification by multinuclear magnetic resonance spectroscopy. Toxicol Lett 2001;123:169-77.
6. Basu, P, Sunny S, Maier C. Estrogenic and antiestrogenic activities of commercial dietary supplements containing herbal ingredients and isoflavones. Int J Pharm Pharm Sci 2016;8:307-12.
7. Volpi N. Hyaluronic acid and chondroitin sulfate unsaturated disaccharides analysis by high-performance liquid chromatography and fluorimetric detection with dansylhydrazine. Anal Biochem 2000;277:19-24.
8. Vatansever B, Binici B. A quantitative method for the measurement of hydrolyzed type-I collagen protein in dietary supplement sirup using HPLC-SEC-UV technique. J Chem Metrol 2015;1:1-15.
9. Podder AK. Qualitative and quantitative analysis of sildenafil in traditional medicines and dietary supplements. Asian J Pharm Clin Res 2014;7:25-30.

| Concentration (μg/mL) | Peak area (μV/s) | Measured concentration (μg/mL) | % Recovery | Average | Standard deviation | KV (%) |
|-----------------------|------------------|-------------------------------|------------|---------|-------------------|--------|
| 4000                  | 53592            | 392.402                       | 99.81      | 99.35   | 0.4010            | 0.40   |
| 53141                 | 5363.404         | 99.09                         |            |         |                   |        |
| 53179                 | 3695.921         | 99.15                         |            |         |                   |        |

Table 14: Quantification data for methylsulfonylmethane levels in supplements